Wagner S J, Skripchenko A
American Red Cross, Biomedical Research and Development, Blood & Cell Therapy Development, Rockville, MD 20855, USA.
Biotech Histochem. 2003 Jun-Aug;78(3-4):171-7. doi: 10.1080/1052029032000140894.
Despite recent advances in blood safety by careful donor selection and implementation of infectious disease testing, transmission of viruses, bacteria and parasites by transfusion can still rarely occur. One approach to reduce the residual risk from currently tested pathogens and to protect against the emergence of new ones is to investigate methods for pathogen inactivation. The use of photosensitizing dyes for pathogen inactivation has been studied in both red cell and platelet blood components. Optimal properties of sensitizing dyes for use in red cell suspensions include selection of dyes that traverse cell and viral membranes, bind to nucleic acids, absorb light in the red region of the spectrum, inactivate a wide range of pathogens, produce little red cell photodamage from dye not bound to nucleic acid and do not hemolyze red cells in the dark. Early research at the American Red Cross focused on the use of a class of dyes with rigid structures, such as the phenothiazine dyes, beginning with the prototypical sensitizer methylene blue. Results revealed that methylene blue phototreatment could inactivate extracellular virus, but resulted in undesirable defects in the red cell membrane that resulted in enhanced hemolysis that became evident during extended refrigerated blood storage. In addition, methylene blue phototreatment could neither inactivate intracellular viruses nor appreciably inactivate bacteria under conditions of extracellualar viral killing. Attempts to improve intracellular viral inactivation led to the investigations of more hydrophobic phenothiazines, such as methylene violet or dimethylmethylene blue. Although these dyes could inactivate intracellular virus, problems with increased red cell membrane damage and hemolysis persisted or increased. Further studies using red cell additive storage solutions containing high levels of the impermeable ion, citrate, to protect against colloidal osmotic hemolysis as well as competitive inhibitors to limit sensitizer binding to red cell membranes revealed that photoinduced hemolysis stemmed from dye bound to the red cell membrane as well as dye free in solution. Use of red cell additive solutions to prevent colloidal-osmotic hemolysis and use of novel flexible dyes that only act as sensitizers when bound to their targets are two techniques that currently are under investigation for reducing red cell damage. Ultimately, the decision to implement a photodynamic method for pathogen reduction will be determined by weighing the risks of unintended adverse consequences of the procedure itself, such as the potential for genotoxicity and allergic reactions, against the cost and benefits of its implementation.
尽管通过仔细筛选献血者和实施传染病检测,血液安全方面最近取得了进展,但输血传播病毒、细菌和寄生虫的情况仍可能极少发生。降低当前检测病原体残留风险并预防新病原体出现的一种方法是研究病原体灭活方法。在红细胞和血小板血液成分中都对使用光敏染料进行病原体灭活进行了研究。用于红细胞悬液的敏化染料的最佳特性包括选择能够穿过细胞和病毒膜、与核酸结合、在光谱的红色区域吸收光、灭活多种病原体、未与核酸结合的染料对红细胞产生的光损伤极小且在黑暗中不会使红细胞溶血的染料。美国红十字会早期的研究集中在使用一类具有刚性结构的染料,如吩噻嗪染料,从典型的敏化剂亚甲蓝开始。结果表明,亚甲蓝光处理可以灭活细胞外病毒,但会导致红细胞膜出现不良缺陷,从而导致在延长的冷藏血液储存期间溶血增强。此外,在细胞外病毒杀灭条件下,亚甲蓝光处理既不能灭活细胞内病毒,也不能显著灭活细菌。为改善细胞内病毒灭活而进行的尝试导致了对更多疏水性吩噻嗪的研究,如甲紫或二甲基亚甲蓝。尽管这些染料可以灭活细胞内病毒,但红细胞膜损伤和溶血增加的问题仍然存在或加剧。进一步的研究使用含有高水平不可渗透离子柠檬酸盐的红细胞添加剂储存溶液来防止胶体渗透压溶血,以及使用竞争性抑制剂来限制敏化剂与红细胞膜的结合,结果表明光诱导溶血源于与红细胞膜结合的染料以及溶液中游离的染料。使用红细胞添加剂溶液来防止胶体渗透压溶血以及使用仅在与靶标结合时才作为敏化剂的新型柔性染料是目前正在研究的减少红细胞损伤的两种技术。最终,实施光动力病原体减少方法的决定将通过权衡该程序本身意外不良后果的风险,如潜在的遗传毒性和过敏反应,与其实施的成本和益处来确定。